Understanding the experiences of multiple myeloma patients treated with CAR T-cell therapy
Survivorship in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell Therapy
This study is looking at how patients with relapsed or hard-to-treat multiple myeloma feel and do after receiving CAR T-cell therapy, aiming to understand their health and emotional well-being to help improve their care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-10934071 on NIH RePORTER |
What this research studies
This research investigates the experiences of patients with relapsed or refractory multiple myeloma who have undergone chimeric antigen receptor T-cell (CAR T) therapy. It aims to establish a diverse cohort of patients receiving this treatment at Moffitt Cancer Center, focusing on both clinical outcomes and psychosocial factors such as anxiety and social support. By evaluating the relationship between these factors and patient health-related quality of life, the research seeks to provide insights that could improve care for this patient population.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with relapsed or refractory multiple myeloma who are receiving CAR T-cell therapy.
Not a fit: Patients who are not undergoing CAR T-cell therapy or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could enhance the understanding of how CAR T therapy impacts the overall well-being and quality of life of multiple myeloma patients.
How similar studies have performed: Previous research has shown promising results with CAR T therapy in multiple myeloma, indicating that this approach has the potential for significant clinical impact.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Oswald, Laura B. — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Oswald, Laura B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.